IL156262A0 - Anti-cd28 antibodies having no mitogenic activity and pharmaceutical compositions containing the same - Google Patents

Anti-cd28 antibodies having no mitogenic activity and pharmaceutical compositions containing the same

Info

Publication number: IL156262A0
Authority: IL; Israel
Prior art keywords: antibodies; same; pharmaceutical compositions; compositions containing; mitogenic activity
Prior art date: 2000-12-14

Application number

IL15626201A

Other languages

English (en)

Original Assignee

Fujisawa Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-14

Filing date

2001-12-14

Publication date

2004-01-04

2001-12-14 Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co

2004-01-04 Publication of IL156262A0 publication Critical patent/IL156262A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Transplantation (AREA)
Surgery (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL15626201A 2000-12-14 2001-12-14 Anti-cd28 antibodies having no mitogenic activity and pharmaceutical compositions containing the same IL156262A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25515500P	2000-12-14	2000-12-14
PCT/US2001/047955 WO2002047721A1 (en)	2000-12-14	2001-12-14	Silensed anti-cd28 antibodies and use thereof

Publications (1)

Publication Number	Publication Date
IL156262A0 true IL156262A0 (en)	2004-01-04

Family

ID=22967074

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15626201A IL156262A0 (en)	2000-12-14	2001-12-14	Anti-cd28 antibodies having no mitogenic activity and pharmaceutical compositions containing the same

Country Status (18)

Country	Link
EP (1)	EP1341553A4 (es)
JP (1)	JP2004515243A (es)
KR (1)	KR20040020866A (es)
CN (1)	CN1272345C (es)
AR (1)	AR031924A1 (es)
AU (2)	AU2608602A (es)
BR (1)	BR0116686A (es)
CA (1)	CA2432736A1 (es)
CZ (1)	CZ20031909A3 (es)
HU (1)	HUP0400697A3 (es)
IL (1)	IL156262A0 (es)
MX (1)	MXPA03005327A (es)
NO (1)	NO20032542L (es)
NZ (1)	NZ526569A (es)
PL (1)	PL363239A1 (es)
RU (1)	RU2261723C2 (es)
WO (1)	WO2002047721A1 (es)
ZA (1)	ZA200305384B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080095774A1 (en) *	2001-02-16	2008-04-24	Wyeth	Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en)	2001-02-16	2009-05-12	Genetics Institute Llc	Method for downmodulating immune response in type I diabetes
ES2776657T3 (es)	2005-06-14	2020-07-31	Amgen Inc	Formulaciones de proteínas autotamponantes
FR2951176A1 (fr)	2009-10-09	2011-04-15	Tcl Pharma	Ligands monovalents du recepteur cd28 humain
ES2896149T3 (es) *	2010-02-18	2022-02-24	Ose Immunotherapeutics	Anticuerpos humanizados anti-CD28
CA3040899A1 (en)	2016-10-21	2018-04-26	Amgen Inc.	Pharmaceutical formulations and methods of making the same
US20210251994A1 (en)	2018-06-15	2021-08-19	Flagship Pioneering Innovations V, Inc.	Increasing immune activity through modulation of postcellular signaling factors
CA3130348A1 (en) *	2019-03-14	2020-09-17	Motti HAKIM	A method for immunosuppression
MA55805A (fr)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V Inc	Métodes de modulation de l'activité immunitaire
EP4076434A1 (en)	2019-12-17	2022-10-26	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN116096906A (zh)	2020-06-29	2023-05-09	旗舰创业创新五公司	工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
KR20230166150A (ko)	2020-08-19	2023-12-06	젠코어 인코포레이티드	항-cd28 조성물
JP2024512669A (ja)	2021-03-31	2024-03-19	フラグシップパイオニアリングイノベーションズブイ，インコーポレーテッド	タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
CA3224374A1 (en)	2021-06-29	2023-01-05	Flagship Pioneering Innovations V, Inc.	Immune cells engineered to promote thanotransmission and uses thereof
CA3252619A1 (en)	2022-02-23	2023-08-31	Xencor, Inc.	Anti-CD28 and anti-PSMA antibodies
EP4572772A1 (en)	2022-08-17	2025-06-25	Capstan Therapeutics, Inc.	Conditioning for in vivo immune cell engineering
WO2024077191A1 (en)	2022-10-05	2024-04-11	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024148336A1 (en) *	2023-01-06	2024-07-11	Igm Biosciences, Inc.	T cell costimulatory multimeric binding molecules and uses thereof
WO2024151687A1 (en)	2023-01-09	2024-07-18	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
US12311033B2 (en)	2023-05-31	2025-05-27	Capstan Therapeutics, Inc.	Lipid nanoparticle formulations and compositions
WO2025076127A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025179294A2 (en)	2024-02-22	2025-08-28	Capstan Therapeutics, Inc.	Immune engineering amplification
WO2025217454A2 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521288A (en) *	1990-03-26	1996-05-28	Bristol-Myers Squibb Company	CD28IG fusion protein

2001
- 2001-12-14 JP JP2002549291A patent/JP2004515243A/ja not_active Withdrawn
- 2001-12-14 EP EP01995504A patent/EP1341553A4/en not_active Withdrawn
- 2001-12-14 CA CA002432736A patent/CA2432736A1/en not_active Abandoned
- 2001-12-14 CN CNB018226361A patent/CN1272345C/zh not_active Expired - Fee Related
- 2001-12-14 HU HU0400697A patent/HUP0400697A3/hu unknown
- 2001-12-14 CZ CZ20031909A patent/CZ20031909A3/cs unknown
- 2001-12-14 KR KR10-2003-7007798A patent/KR20040020866A/ko not_active Ceased
- 2001-12-14 WO PCT/US2001/047955 patent/WO2002047721A1/en not_active Ceased
- 2001-12-14 NZ NZ526569A patent/NZ526569A/en unknown
- 2001-12-14 IL IL15626201A patent/IL156262A0/xx unknown
- 2001-12-14 RU RU2003121231/15A patent/RU2261723C2/ru not_active IP Right Cessation
- 2001-12-14 AU AU2608602A patent/AU2608602A/xx active Pending
- 2001-12-14 PL PL01363239A patent/PL363239A1/xx not_active Application Discontinuation
- 2001-12-14 BR BR0116686-7A patent/BR0116686A/pt not_active IP Right Cessation
- 2001-12-14 AU AU2002226086A patent/AU2002226086C1/en not_active Ceased
- 2001-12-14 AR ARP010105828A patent/AR031924A1/es unknown
- 2001-12-14 MX MXPA03005327A patent/MXPA03005327A/es unknown
2003
- 2003-06-05 NO NO20032542A patent/NO20032542L/no not_active Application Discontinuation
- 2003-07-11 ZA ZA200305384A patent/ZA200305384B/en unknown

Also Published As

Publication number	Publication date
MXPA03005327A (es)	2004-12-03
JP2004515243A (ja)	2004-05-27
AR031924A1 (es)	2003-10-08
RU2261723C2 (ru)	2005-10-10
NZ526569A (en)	2005-07-29
CA2432736A1 (en)	2002-06-20
RU2003121231A (ru)	2005-02-10
NO20032542D0 (no)	2003-06-05
CN1489473A (zh)	2004-04-14
HUP0400697A3 (en)	2007-05-02
WO2002047721A1 (en)	2002-06-20
NO20032542L (no)	2003-08-07
EP1341553A1 (en)	2003-09-10
KR20040020866A (ko)	2004-03-09
HUP0400697A2 (hu)	2004-06-28
BR0116686A (pt)	2003-12-30
AU2002226086B2 (en)	2005-08-25
EP1341553A4 (en)	2004-07-28
CN1272345C (zh)	2006-08-30
AU2608602A (en)	2002-06-24
PL363239A1 (en)	2004-11-15
CZ20031909A3 (cs)	2003-11-12
AU2002226086C1 (en)	2006-03-09
ZA200305384B (en)	2004-10-11

Publication	Publication Date	Title
IL156262A0 (en)	2004-01-04	Anti-cd28 antibodies having no mitogenic activity and pharmaceutical compositions containing the same
HUP0200714A3 (en)	2003-01-28	Pharmaceutical compounds, pharmaceutical compositions containing them and their use
ZA200110022B (en)	2003-05-28	Thiazoloderivatives and pharmaceutical compositions containing them.
HUP0302969A3 (en)	2005-05-30	Npyy5 antagonists, pharmaceutical compositions containing them and their use
IL138280A0 (en)	2001-10-31	20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
HUP0204514A3 (en)	2004-07-28	Pyridinylimidazoles, pharmaceutical compositions containing them and their use
HUP0301777A3 (en)	2010-09-28	Aniline-derived ligands for the thyroid receptor, pharmaceutical compositions comprising thereof and their use
HUP0204413A3 (en)	2003-07-28	Quinazoline compounds, their preparation, their use and pharmaceutical compositions containing them
HUP0204081A3 (en)	2003-07-28	4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
HUP0203939A3 (en)	2004-12-28	Pharmaceutical compounds and compositions containing them and their use
GC0000307A (en)	2006-11-01	Pyrimidone compounds and pharmaceutical composition containing them
HUP0301573A3 (en)	2004-03-29	Substituted arylpyrazines, pharmaceutical compositions containing them and their use
HUP0103884A3 (en)	2002-11-28	Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use
HUP0402566A3 (en)	2009-01-28	C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them
HUP0200312A3 (en)	2002-12-28	Substituted 2-phenylbenzimidazoles, pharmaceutical compositions containing them, the production thereof and their use
IL150224A0 (en)	2002-12-01	Lipopeptides and pharmaceutical compositions containing the same
HUP0102372A3 (en)	2003-01-28	Dihydropyrimidines, preparation thereof and pharmaceutical compositions containing the same
IL150223A0 (en)	2002-12-01	Lipopeptides and pharmaceutical compositions containing the same
IL153463A0 (en)	2003-07-06	Pharmaceutical compositions comprising activated antibodies
IL144910A0 (en)	2002-06-30	Cyclic compounds and pharmaceutical compositions containing the same
IL164021A0 (en)	2005-12-18	Antibodies and anti-pharmaceutical compositions containing the same
HUP0204071A3 (en)	2003-07-28	Nitrogenous cyclic compounds and pharmaceutical compositions containing the same and their use
ZA200202996B (en)	2003-06-25	Hair treatment compositions comprising particulate substances.
IL136938A0 (en)	2001-06-14	11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
HUP0202781A3 (en)	2003-10-28	Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use

Legal Events

Date	Code	Title	Description
2006-02-21	HC	Change of name of proprietor(s)